Progress in EIF5A2 gene in malignant tumors / 肿瘤

ABSTRACT

Eukaryotic translation initiation factor 5A2 (EIF5A2) is a small universally conserved acidic protein classified in the EIF family. It has been found that EIF5A2 is widely over-expressed in various carcinomas, such as lung cancer, breast cancer and cervical cancer. EIF5A2 mainly promotes the occurrence and development of carcinoma by inducing epithelial-mesenchymal transition. A combination therapy with N1-guanyl-1, 7-diaminohep-tane (GC7), ciclopirox (CPX) and cytokines pharmacological agents can inhibit the activity of EIF5A2 through interfering the process of hypusine post-translational modification, and it is expected to be a good choice for clinical medication. Studies have shown that EIF5A2, as a carcinogenic gene, may be an effective molecular biomarker in the diagnosis and treatment of cancer. This review summarizes the progress in EIF5A2 in carcinoma.